Open AccessAn Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity
Author(s) -
Tim Wirt,
Sophia Roßkopf,
Thies Rösner,
Klara Marie Eichholz,
A. K. Kahrs,
Sebastian Lutz,
Anna Kretschmer,
Thomas Valerius,
Katja Klausz,
Anna Otte,
Martin Gramatzki,
Matthias Peipp,
Christian Kellner
Publication year - 2017
Publication title -
transfusion medicine and hemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.971
H-Index - 39
eISSN - 1660-3818
pISSN - 1660-3796
DOI - 10.1159/000479978
Subject(s) - antibody dependent cell mediated cytotoxicity , antibody , fucosylation , cytotoxicity , fragment crystallizable region , complement dependent cytotoxicity , protein engineering , cd20 , chemistry , fucose , monoclonal antibody , microbiology and biotechnology , cancer research , immunology , biology , biochemistry , glycoprotein , in vitro , enzyme
Engineering of the antibody's fragment crystallizable (Fc) by modifying the amino acid sequence (Fc protein engineering) or the glycosylation pattern (Fc glyco-engineering) allows enhancing effector functions of tumor targeting antibodies. Here, we investigated whether complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20 antibodies could be improved simultaneously by combining Fc protein engineering and glyco-engineering technologies.